Despite the XBI’s 27% drop since Trump’s election and widespread market uncertainty, Q1 2025 biotech dealmaking and venture funding showed surprising underlying stability, particularly in licensing, M&A, and Phase 2 asset deals. Data from DealForma highlights the rapid rise of Chinese biotechs, now accounting for 42% of major licensing deals, while Big Pharma continues to prioritize mid-stage assets. Read the article here
